DaVita Inc. (DVA) Earnings Call Transcript & Summary
October 28, 2022
Earnings Call Speaker Segments
Joel Ackerman
executiveThanks, and good morning to all of you on our Q3 earnings call. We're grateful that you keep following what's happening at our company. My name is Joel Ackerman, and I serve as CFO and Treasurer; with me this morning is Javier Rodriguez, who holds the CEO role. Keep in mind that we might offer forward-looking statements on this call as defined under the federal securities laws. Every one of those statements carries known and unknown risks along with uncertainties, which might lead actual results to diverge materially from what those forward-looking statements describe; if you want more specifics about such risks and uncertainties, turn to our Q3 earnings press release plus our SEC filings, among them our latest annual report on Form 10-K, every later quarterly report on Form 10-Q, and any other filings we subsequently submit to the SEC. The information we currently have forms the basis for our forward-looking statements, and aside from situations where the law demands it, we neither plan to nor bear any obligation to revise them. Also, a reminder: certain non-GAAP financial measures will come up during this call. You can find a reconciliation between those non-GAAP measures and the closest GAAP financial measures in our earnings press release, which we furnished to the SEC and which sits on our website. At this point, I'll hand things over to Javier Rodriguez.
Javier Rodriguez
executiveThanks, Joel. Morning, everybody, and thanks for being on the call with us today. For us, Q3 was a tough quarter. Although the actual COVID figures have been going down, the accumulated effect of COVID on the ESKD patient population keeps getting larger. Even with the economic difficulties, we keep providing high-quality clinical care to those we treat. We stay deeply thankful for the incredible efforts of our frontline teammates, who never waver in their dedication to patient care. Our dedication to patients never changes, yet it stands out most when a community is suffering. As you're aware, Hurricane Ian came ashore in Southwest Florida on September 28, exposing that community to sustained winds of 100-plus miles per hour and major flooding; this created numerous health and safety problems for residents there, particularly those needing dialysis to stay alive. In Florida, DaVita runs 230 dialysis centers, serving roughly 14,000 patients with 3,250 teammates. Thanks to our thorough preparedness planning, I'm thankful that 100% of our patients were accounted for, and every one of them had gotten dialysis within days after the hurricane made landfall; we sent water tankers, generators, and fuel tankers to swiftly bring operations back in the impacted areas and to deliver dialysis to patients throughout the kidney care community; now let's move to our financial results. As I said, the quarter was a difficult one. In Q3, adjusted operating income came to $351 million, while adjusted earnings per share was $1.4%5. Compared with Q2, adjusted operating income fell by $88 million sequentially and came in under what we had expected for the quarter. Volume headwinds have lasted longer than we projected, and contract labor costs along with productivity failed to start improving during the quarter the way we thought they would; we now expect these pressures to persist beyond what we previously anticipated. Because of that, and with ongoing uncertainty from COVID and the labor market, we are cutting our guidance for the year and our outlook for 2023 too. We are bringing our 2022 adjusted operating income guidance down to a range of $1.375 billion to $1.45 billion, and our 2022 adjusted EPS guidance down to $6.20 to $6.70 per share. For 2023, we're revising our outlook for year-over-year adjusted operating income growth to negative $50 million to positive $150 million, as laid out in our press release for this quarter. As we've noted before, volume and labor remain the largest sources of uncertainty in our results. Let me take you through the specifics of what we've observed on each and what we're assuming ahead. Let's begin with the three primary drivers of volume. Census growth before excess mortality, net treatment rates and excess mortality. I'll address each one separately. First, regarding census growth, not counting excess mortality, we've observed a drop in patient admissions during every COVID surge, with a rebound following each surge. The downturn observed earlier in 2022 stemmed from Omicron, and our expectation was that it would bounce back during the latter half of the year, just as happened following previous surges. That anticipated recovery failed to materialize in Q3, so we are now building in ongoing strain on admissions for Q4 and throughout 2023. Turning to net treatment rates: during our Q1 earnings call, we noted that mid-treatment rates had climbed because of Omicron, and those rates were significantly affecting the movement in our treatment volume. Our assumption was that once the surge subsided, those increases would revert to seasonal norms — yet they have not. Consequently, we now assume they will stay elevated until this year ends and across 2023. Last, on excess mortality: although mortality tied to COVID during 2022 has fallen compared with earlier years, excess mortality continues to pose difficulties for us. We anticipate this will carry on in Q4 and into 2023. How large the effect turns out to be hinges on the scale and seriousness of COVID surges this winter and over the remainder of 2023. When you combine these three metrics, volume stands as the greatest source of uncertainty in our forecast covering Q4 2022 and 2023. Shifting to labor, I'll address three drivers: wage rate, contract labor, and training costs. As mentioned previously, we built in considerable wage pressure for 2022, partly offset by reduced benefit costs. All told, we projected a headwind of roughly $100 million to $125 million in 2022. So far this year, our results align with that projection; we likewise encountered substantial pressure from contract labor expenses during the first half; we anticipate those will stay elevated in Q3, though below Q2 levels. In reality, Q3 contract labor cost rose compared with Q2, and our new forecast is that the decline will arrive later and more gradually than we first assumed. Regarding training, we entered Q3 with higher costs stemming from additional hires, matching the increases observed historically at hiring peaks. Training costs sped up in Q3, producing roughly $20 million more in costs for the quarter than we had expected. Given elevated turnover, this has yet to generate the scale of positive effect we would ordinarily anticipate on contract labor or staffing level. Therefore, we expect training costs to stay elevated in Q4 and early 2023; to address these difficulties, we keep pursuing multiple cost-saving initiatives for 2023. First, we anticipate meaningful savings from our new anemia management contract. We will start transitioning to our new Mircera contract in 2023. Second, we are optimizing our clinic footprint for the present operating environment, which we expect will yield higher capacity utilization and improved leveraging of our clinic fixed costs, labor costs included. To wrap up, we've got efforts in motion aimed at trimming our G&A across a number of business areas, even as we keep putting money into what's ahead. As we've talked about, the compounding, ongoing impact of COVID along with labor conditions are the main forces behind the revised view we now hold for the rest of 2022 and into 2023. We had foreseen that volume loss tied to COVID plus pressure in the labor market would weigh on revenue growth and margins during 2022, and so we figured 2023 would bring relief on both fronts. What we're assuming now is that these difficulties will last further out than we originally thought, and that's the reason our guidance has moved. Taking a broader view, our confidence in the strategy hasn't wavered, and our attention is on answering today's sector-wide obstacles. We're committed to providing high-quality care for our patients, building a wonderful workplace for our teammates, and maintaining our future-focused investment so we can fuel growth in integrated kidney care, treat more patients at home, and widen access to transplant. At this point I'll hand things over to Joel, who will walk through our financial results and outlook in more depth.
Joel Ackerman
executiveThanks, Javier. Before I move on to what's left of 2022 and then 2023, let me add a handful of specifics about the third-quarter results. As Javier said, treatment volume pressure and elevated labor costs persisted in Q3; those headwinds were partly cushioned by ballot initiative spending coming in under plan and by smaller-than-anticipated ITC losses during the quarter. Ballot initiative spend came to $28 million in the quarter, versus $23 million in the prior quarter; within IKC we booked a benefit of roughly $8 million tied to shared savings revenue we had expected in Q4, and that amount could be offset by ITC losses in Q4 that run higher than we expect. Compared with the second quarter, U.S. dialysis treatments per day fell 0.4%. Roughly half of that decrease came from elevated miss treatment, with the other half from a lower census. Quarter-over-quarter, revenue per treatment rose by $2.13, driven mainly by favorable adjustments, more acute treatment, and the ongoing shift toward MA plans, partly offset by Medicare sequestration being reinstated. Patient care cost per treatment climbed $8.72 versus the prior quarter, largely on account of higher wage rates, training expenses for new teammates given increased hiring, and the timing of teammate health benefit expenses. G&A expense rose about $56 million from Q2, and $46 million of that $56 million stems from three items. First, Q2 included a onetime gain of $22 million on some self-developed properties. Second, Q3 carried $11 million of recognized expense tied to closure charges; that $11 million sits outside adjusted OI. Third, we made our $28 million contribution to the industry campaign opposing the California ballot initiative, which is $5 million more than in Q2. The remainder of the quarter-over-quarter change reflects higher compensation expense and the usual swings in G&A spend. As I've noted on earlier calls, we've pinpointed a set of initiatives aimed at reducing our fixed cost structure and our G&A. In connection with those efforts, during Q3 we recorded $40 million of expense, including accelerated depreciation and the write-off of net book value on assets at certain centers we shut down as we work to optimize our clinic footprint. Those expenses fall outside our adjusted operating income; we expect further expenses will be excluded from adjusted operating income in our guidance for 2022 and 2023 alike. I'd also like to provide a few details on 2023. As Javier said, we've revised our estimate for year-over-year adjusted operating income growth to a range of negative $50 million to positive $150 million. That shift stems mainly from our assumptions regarding the ongoing treatment volume headwind. We've also made minor changes to two other drivers. First, we've revised the labor cost outlook, chiefly for training costs of new hires now pushed into 2023 because of 2022 performance and inflation. We've also reduced by $25 million the range for year-over-year improvement in IKC operating income. The reason for this comes down to how well we did in 2022, not any revision to what we expect for 2023. Also, over the quarter, we bought back roughly 2.1 million shares, taking the 2022 tally so far to about 8.1 million shares. Going ahead, we anticipate a meaningful slowdown in how quickly we repurchase shares. At present, our plan is to direct a greater portion of capital toward paying down debt so we can return to our target leverage ratio of 3 to 3.5 times EBITDA. Operator, please open the call for Q&A.
Andrew Mok
analystHello, good morning. I’m grateful for all the detail regarding the headwinds. Looking at the guidance, it suggests a Q4 span of roughly $240 million to $320 million of OI, which represents a fairly significant drop from prior quarters. Could you perhaps help put in order the headwinds you described for us, in terms of what is causing the sequential decrease? Also, what assumptions are you making about COVID and how it affects treatment and labor during Q4? Thank you.
Javier Rodriguez
executiveCertainly. Thank you, Andrew, for asking; so if I were to connect Q3 to the midpoint of the range for Q4, First, there’s the gain from ballot. That comes to a benefit in the high $28 million. Regarding the headwinds, ranking them, 1 and 2 are salary wage and benefit, which would be first. That includes greater training expenses, higher wage rates and some seasonality in benefits. Second would be volume, which reflects the accumulated census shortfall. That means essentially the entire quarter’s impact from the reduced census we had in Q3, along with further census pressure and a surge in the mist treatment rate. In the past, mistreatment rates are at their lowest in Q3 and Q4 — sorry, in Q2 and Q3, they rise in Q4 and then once more in Q1, in part because of weather and flu season and also in part because of holidays; and then third would be RPT; we enjoyed some positive variability in Q3, that will decrease, and we usually observe a slight drop in commercial mix from mid-year through year-end. So those are the main ones. I believe there’s a small amount related to depreciation and amortization. I think IKC will also decline a bit again, and there is some seasonality in G&A. So that would be the bridge regarding what we are assuming here for Q4, we are assuming ongoing excess mortality, we are assuming the — the mistreatment rate that we have observed being above historical norms continues; and we are assuming some of the admissions or the — the, let’s say, organic growth difficulties that we saw in Q3, we are assuming those continue too.
Andrew Mok
analystUnderstood. All right.
Joel Ackerman
executiveAndrew, allow me to provide a bit of context regarding what you're calling magnitude. One thing worth highlighting is that beneath every assumption Joel just walked through sits a shift in philosophy about how we view what lies ahead. Previously, our models incorporated a bounce-back; we factored in the unknowns, yet assumed they'd fade away roughly by Q3 and certainly through Q4. What we're doing now is presuming that COVID persists, and that unpredictability around labor and volume endures for a longer stretch. That is what moves the models in the drastic manner you're attempting to reconcile.
Andrew Mok
analystUnderstood. All right, that's useful. Is there anything you can share about the extent to which the mistreatment rate in 2022 exceeds what we've seen historically?
Javier Rodriguez
executiveYes, it's roughly 100 basis points greater — so consider that simply a 1% drag on the volume of treatments we handle. And to put a figure on it, 1% of treatment volume equates to roughly $50 million in operating income.
Andrew Mok
analystUnderstood. Next, you said that contract labor expenses were up on a quarter-over-quarter basis, and that pattern is a bit unexpected. Did greater utilization cause it, or did higher rates? Also, did any particular markets account for that quarter-over-quarter rise?
Javier Rodriguez
executiveYeah. I'll take that question. The truth is no single market is responsible. This is happening nationwide. The reason that item — contract labor — is acting in a way that's harder to anticipate than it typically does comes down to this: ordinarily, you'd treat your training as an early signal that contract labor will fall later on, meaning you're bringing a teammate up to speed and that individual will be on the floor in roughly 3, 4 months. Then you'd basically project a decline in contract labor, since turnover tends to persist. Sadly, our early signal from training is resulting in less contract labor, so instead we've got more contract labor alongside more training, which is obviously the double whammy we've been discussing.
Andrew Mok
analystUnderstood, that clears things up. Then you brought up..
Joel Ackerman
executiveTo build on what Javier said, the key factor is how many contract workers there are, not the rate itself.
Andrew Mok
analystAll right, that's useful. For my final question, I'll rejoin the queue afterward. You said there's a plan to move your ESA regimen from Epogen to Mircera <<inaudible>> during 2023. Could you give us some insight into how quickly that change will happen?
Joel Ackerman
executiveSure. This topic has come up quite a bit. Naturally, nothing matters more than safety, and we intend to proceed at an appropriate speed. The transition will be complete at some point in 2023, though physicians obviously need to go through every protocol and confirm it suits the patients they treat. Because of that, we aren't setting any specific target. What we're asking is simply this: examine the paperwork and issue the correct prescription for your patients.
Andrew Mok
analystOkay. Thank you.
Joel Ackerman
executiveThank you.
Kevin Fischbeck
analystThank you. I'd like to dig into this missed-treatment situation a bit. Has this kind of thing occurred previously? What makes patients skip sessions repeatedly — it feels like that can't go on for a long stretch. So has it occurred before, and typically how many days until they return? And what do you believe is driving it currently and making it last longer?
Javier Rodriguez
executiveSure, Kevin, I appreciate that. Skipped sessions do occur at particular volumes, since life gets in the way — rides, time away, and so on — and you skip a single session. Your assessment seems correct that there isn't what I'd term a persistent skip, because you can't go without dialysis for an excessive stretch. Yet once we examined the data, it showed a concentration: about 15% of patients account for 70% of the skipped sessions. So as we dug in, we discovered that close to half of the skipped sessions stem from hospital stays. The remaining half comes from a mix of factors: the patient himself or herself being sick with COVID or another illness, thus remaining at home; transportation problems, whether from staffing or other causes; and then scheduling — whether because of the patient or our center. So many elements feed into the skipped session — and what we're attempting to do at present is ensure we intensify our efforts to get patients rescheduled, but this is where everything ties together. When the labor market is tight and staffing is constrained, rescheduling sometimes becomes more difficult — so we're addressing it. And essentially, we had never truly discussed this treatment since it was fairly level year-over-year. Then, with the arrival of COVID, so to speak, that figure began to shift, and we assumed it would return to where it was, and we're now observing that it remains elevated.
Kevin Fischbeck
analystAll right, that's clear. Then I suppose, what was behind the commercial mix during the quarter? My understanding is that it acted as a headwind in this period, yet served as a tailwind across the year so far. So is there anything happening there? Do you have any updates or views regarding whether Marriott is having any effect on pricing?
Javier Rodriguez
executiveYes. No. Commercial mix came in roughly flat, and it declined. It fell in what I would describe as an ordinary significant manner on the commercial side. And you have to keep in mind that mix involves both a numerator and a denominator, and given excess mortality, especially among our older population, which is Medicare, that figure is shifting somewhat atypically too. But there is nothing worth reporting about that.
Kevin Fischbeck
analystWhen it comes to pricing, is Marriott making any kind of difference there?
Javier Rodriguez
executiveNot at all. Regarding pricing, as I recall, we lock in our contracts for a long stretch of time — so if you wanted to frame the downside of how we price over the long term, it's that they obviously failed to account for the inflation we're all seeing. If you want to consider the upside, and this is something we've discussed before, it's that our relationships with our payers are highly predictable and steady; as a result, you aren't exposed to the jolts of daily life, and you can plan on a 3-, 4-year horizon.
Kevin Fischbeck
analystOkay, fine, thank you.
Pito Chickering
analystMorning, everyone, and I appreciate you letting me ask. If we look back at 2Q, when you folks shared results at the start of August, I'm wondering what shifted during August and September compared with what was seen across July, which explains the guidance shortfall that was so dramatic?
Javier Rodriguez
executiveSure. I'll take the big picture here, and I may repeat myself somewhat — what it really comes down to, Peter, is that guidance underwent a philosophical shift. So consider this: we believed there was a rebound, and we figured plenty of those elevated figures would return to normal. A few were mentioned specifically — training and miss treatments among them — and once you take all of those figures together and assume they'll return to normal, what actually happens is they hit an all-time high, which means they move in the reverse direction. That's when a large gap begins to appear — and rather than assuming the rebound might arrive a quarter later, we simply stated that no data exists that would let us get any better at truly forecasting when this turns. So internally we talked it over, and a few possibilities were on the table. There were 3 options, correct? Option one: provide no guidance whatsoever, since predicting 2023 is simply too difficult. Option two: attempt to forecast the unforecastable — genuinely try to make an informed guess about when COVID and labor markets settle down. Then option three: presume today's conditions hold steady until clear data emerges. Previously we leaned toward something like Option 2, meaning we built in assumptions about COVID in volume and expected improvement late in '22 and further gains going into 2023. At this point, though, we're closer to adopting 3, meaning we presume these odd dynamics around COVID volumes and the labor markets persist until more data comes in.
Joel Ackerman
executivePeter, I'd like to add some numbers to the big-picture view Javier gave. If we compare our '22 guidance as it stands now with where it stood three months back, the midpoint of the range has fallen roughly $150 million. Volume accounts for the largest piece of that, and I'd describe it as about an even 50/50 division between a softer census and a bigger miss on the treatment rate. As for that treatment rate, the issue isn't that it keeps climbing. Rather, it simply isn't declining at the pace we'd expected, and that covers 22. Turning to what shifts in 2023, volume matters considerably more. Once again, census is the primary factor there, and miss treatment rates also aren't falling under our new philosophy. Labor would then be the other major element. Tow thirds training one contract. What that really involves is shifting things from the back half of this year into the front half of next year, at which point we begin to see gains from some of the new hires we're bringing aboard, along with lower training costs and, in the end, reduced contract volume; so those are the figures.
Pito Chickering
analystAll right. Regarding assumptions about treatment—or really treatment itself—I suppose, in Q3, let's set aside the mistreatments for a moment. If I were to separate out the three main drivers, they'd be the incidence rate among new ESRD patients, mortality among patients, and extra deaths caused by COVID. Could you unpack what happened this quarter across those 3 areas? Also, is incidence slowing, which might explain a reduced promotional mix during the quarter and in the back half of the year?
Javier Rodriguez
executiveYeah. Let me pull those up, since your components are correct. We'll begin at the top. You begin with new admits. New admits have fallen by about a couple of thousand patients, after which you deduct transplants, which have stayed roughly flat, after which you deduct mortality, which, as we've talked about, has run higher; after that you deduct the miss treatments, which, as we already covered, have run higher, around 100 basis points depending on where you start. That is the whole equation. The follow-up question, which we've been examining closely, is why new admits have fallen—what's going on with the population upstream, which is the obvious thing to ask. Sadly, that produces an unsatisfying response, and that's due to what we've said throughout, namely that visibility into the CKD population is extremely limited, and about half of patients in fact crash into dialysis. So you begin tapping many different data sources and data sets—and what we've examined is not conclusive. So at present, the hypothesis—someone could hold a solid hypothesis—is that there happens to be somewhat more depth within that patient population. Some others believe that could be offset eventually, since the volume and the pace at which someone progresses from CKD into ESKD will be greater post time as COVID advances. So at present, sadly, once again, the upstream is where we have the least visibility, while the other variables we've already covered.
Pito Chickering
analystAll right, understood. I realize you're not providing revenue guidance for 2023, but given this fairly significant reduction to the OI guidance, could you help point us toward what revenue growth you're assuming for 2023 versus 2022, taking into account all of these changes we're making?
Javier Rodriguez
executiveYes. So the key pieces to focus on, I'd say, are RPT and volume. And at a very high level, my view is that those two will cancel each other out in the coming year. So again, I'd rather not go into too much detail, but I think if you consider RPT in perhaps a slightly improved range, and then a decline in volume — if you take everything we've discussed at the midpoint of the range, that works out to roughly a 2% volume decline — so those two would cancel each other out and leave us at essentially flattish revenue.
Pito Chickering
analystGreat, thank you very much.
Justin Lake
analystThanks, good morning. Just a quick follow-up first regarding the volume question. So you guys are assuming volumes will be down 2% for next year, just to be clear?
Javier Rodriguez
executiveYes.
Justin Lake
analystJustin Lake asking about how the mix is being handled?
Javier Rodriguez
executivewhen you compare one year to the next, there is no effect from mistreatment, since essentially our point is that during 2022 it is operating at a level 100 basis points above the usual, and our assumption is that it will keep operating at that level, 100 basis points above the usual; therefore it stands at 100 basis points compared with pre-COVID, yet measured against the prior year, nothing has shifted.
Justin Lake
analystUnderstood. So this comes entirely from fresh admissions that are lower than mortality?
Javier Rodriguez
executiveYes. What I mean is that it's fresh admissions coming in under what they used to, combined with ongoing excess deaths — and then another key point to keep in mind is that because we had excess deaths all through 2022, that drags down the full year-over-year comparison once that mortality effect laps.
Justin Lake
analystAll right. Then you mentioned the clinic closures during Q3. Could you share the number of clinics that shut down in the third quarter? And what figure do you anticipate for closures across the entire year? Also, do you have any details on how many were closed back in 2023?
Javier Rodriguez
executiveAbsolutely, Justin. There's some timing involved when looking at the full year. So we'd put the range at somewhere between $130 million and 150 for that period. As for the coming year, our projection sits between 50 and $60 million; and once more, timing could cause those to shift. Just as a reminder, since I believe we discussed this previously, we examine things through a few different angles. First, we want to confirm patients have proper access. Second, we check whether home is available — and finally, we consider the dynamics of the local market, looking at leases and similar factors; however, this is a complex process requiring careful thought so that we act responsibly.
Joel Ackerman
executiveJustin, that figure came to 44.
Justin Lake
analystAll right, understood. Then could this also affect how much our patient base grows? Or is it your view that when a center shuts down, we keep nearly all of those patients, close to 100%?
Javier Rodriguez
executiveKeeping 100% isn’t what happens, yet we do hold onto most of them, so volume shouldn’t be affected very much.
Justin Lake
analystAll right. Then, one more thing before I return to the leverage topic; so — would you say EBITDA for next year lands around the $2 billion mark?
Javier Rodriguez
executiveGetting into the details isn't something I want to do; but if leverage is what you're curious about, this quarter we round up to 3.9%. That sits above our target range of 3 to 3.5x. And we are — over the course of next year, we'd like to bring that leverage down. Clearly, how EBITDA moves year-over-year is going to be a key factor in that. But to push that effort further, we're definitely going to reconsider how much free cash flow goes toward share buybacks and shift more heavily toward paying down debt. So the revolver went from 450 last quarter to a drag of $275 this quarter. And it's fair to say our pace of share buybacks will decline over the next year and our leverage level ought to decline too — I'm sorry, our total leverage ought to decline too.
Justin Lake
analystYeah, Joe, I suppose my aim was this — the figure sitting in your press release looks somewhat to the past. If EBITDA arrives with OI declining to 1.4 next year, my assumption is you land around $22.1million of total EBITDA, correct, including the D&A — that would bring you nearer. In the release, I believe you mentioned 8.8% net debt, which would place you at almost 4.4% on a forward-looking basis, as opposed to the backward view contained in that release — first, is that figure accurate? Second, I value the assistance and the explanation regarding paying down debt versus share repo. Still, could you offer a bit more detail: assuming $1 of free cash flow in the coming year, perhaps tell us that in the past it was 100% directed to share repo. Is the split now 75 to 25, or at 4.4 times, are you repurchasing any shares so you move nearer to 3.5%? Thanks.
Javier Rodriguez
executiveYes. I'd begin from a larger EBITDA figure for the coming year. Taking, I believe, the midpoint of our range, you arrive somewhere just above $1.45 billion. I think that's 1.46% on OI, then add back $700 million of depreciation and amortization, and you'd reach an EBITDA figure sitting more within the 21% to 22% range; then regarding the portion of free cash flow we put to work, my thinking is it would be a larger percentage going to debt reduction than that roughly 75%, 25% split. I won't provide a precise number, though I believe we will significantly scale back share buyback.
Justin Lake
analystUnderstood. That helps a lot, folks. Thanks.
Pito Chickering
analystHi, everybody. I've got what's more or less a follow-up question. If I look only at Q4 and take the implied OI and annualize it, that figure comes in significantly below what we're now expecting for '23. So I'm wondering which costs in 4Q were more one-off in nature — things we shouldn't treat as a run rate as we move into 2023?
Javier Rodriguez
executiveAbsolutely. Let me attempt to construct that bridge from Q4 annualized over to the 2023 guide. I believe you end up facing a gap of roughly $350 million that has to be bridged; here's my approach. To start, volume becomes a headwind when going from Q4 to the full year, let's say $100 million, while RPT turns into a tailwind exceeding $200 million. I think it's key to recognize, once more, that in our view RPT will perform more strongly next year, on a year-over-year basis, than it has historically. A major factor behind that is Medicare fee-for-service, where the final rule hasn't been released yet — we expect it any moment now; our anticipation is that this final rule will come in better than the preliminary version. That provides support to RPT, plus you have all the usual RPT increases, so let's put that at more than $200 million. On top of that, I'd include $150 million in cost savings, which appears in the table we highlighted in the press release — and separately there's some unfavorable seasonality in Q4 that's likely worth somewhere between $50 million and $75 million. Adding all of those together puts you at approximately 350. One item I didn't have on my list, which I want to call out, is labor: compared with Q4, we could view 2023 as roughly flat. Labor flat across 2023 versus Q4. What's happening there is that increased wage rates get offset by reduced training costs, which we anticipate declining during the back half of the year, along with contract labor decreasing over time.
Pito Chickering
analystAll right, understood. Then I realize compared with the remaining shifting elements of the smaller one, but regarding the ITC outlook for 2023. I suppose what exactly is altering your forecasts? Are you assuming better utilization? Are you assuming reduced reimbursement? Are you assuming bigger investments? Roughly what is causing that shift for ITC in 2023?
Javier Rodriguez
executiveMy apologies, Pito, I didn't catch that. Would you mind saying the question again? I'm sorry.
Pito Chickering
analystMy apologies. When we look at the 2023 guidance, before, you were steering toward — specifically regarding the ITC — you were steering toward a tailwind, and now it's a $25 million headwind, or to a flat headwind; so there's a swing here in the ITC guidance for next year. I'm just curious what exactly is causing that? Is it more utilization — is it — was that the main reason for the delta?
Javier Rodriguez
executiveYes. Sorry about that. So if I look at 23 for IKC, I think there are really 2 factors at play here when bridging it from 22 to 23. One is 22% is coming in a lot better than we expected. So you're comping to a much smaller loss. The second thing is we now expect growth in 2023 again. And as we've called out in the past, IC growth is a headwind in year 1 to OI; so your — the overall result hasn't changed much. It's that 22 has gotten better and to some extent, some of the benefit we're seeing in '22 is going to get offset by the impact of growth in '23.
Pito Chickering
analystDoes that expansion stem largely from additional MA agreements turning into...
Javier Rodriguez
executiveThat's part of it, though mostly what's driving it is that we're significantly scaling up the CKCC offering. We ran 11 of them during this year, and next year we'll add 11% on top of that. MA will pick up somewhat, yet the dependable, high-volume piece is going to be government.
Pito Chickering
analystAlright, that's reasonable. Then, considering all those shifting pieces, would you say ICE's breakeven point is improving or deteriorating compared with what you previously guided?
Javier Rodriguez
executiveI'd say the business is doing better than we anticipated. However, over the near term, expansion drags down NOI.
Pito Chickering
analystOkay, great. Thanks so much.
Javier Rodriguez
executiveThank you.
Andrew Mok
analystHello. To start with, can you provide us with the excess mortality figure for the quarter? You also mentioned that annualizing excess mortality will be a drag on the upcoming year. As you examine the patient population, is there any sign that mortality rates have come down for the existing population, meaning that once you're done annualizing this excess impact, treatment growth should begin to pick up?
Javier Rodriguez
executiveYes. Excess mortality during the quarter came in slightly above 1,000 — roughly $1,100. Regarding whether we are observing what we refer to as the pull-forward effect, it's extremely difficult for us to separate higher COVID mortality from lower mortality tied to pull forward. Consequently, the excess mortality figure we report is essentially a blend, or a net, of those two figures. We continue to believe in the pull-forward concept — that some patients in our census are being helped by lower mortality stemming from the earlier excess mortality — but we simply cannot quantify it. So it's reasonable to view our excess mortality as a net figure: the number of patients in the quarter who died because of COVID, offset by lower mortality from the prior mortality that isn't happening this quarter. I hope that's clear.
Andrew Mok
analystAll right, that makes sense to me. Then regarding the hurricane, you mentioned that every patient in Florida could still reach dialysis services while the storm was affecting the area. Could you put a number on what that meant for your P&L during this quarter? And does the hurricane carry any remaining effect into Q4?
Javier Rodriguez
executiveYes, Andrew, the P&L saw no meaningful effect, and once more, there is nothing for Q4 on that front.
Andrew Mok
analystAll right, and regarding the Medicare rate — I believe you mentioned that improved Medicare rates are already baked into your assumptions. Does that mean an improvement of 100 basis points? Could you share some detail about what you're factoring in there?
Javier Rodriguez
executiveYeah, that estimate seems fair. We've examined the gap other industries experienced between what they initially had and what they ended up with — so a figure of 3.4% strikes us as sensible, in my view.
Justin Lake
analystIs this coming through clearly on your end?
Javier Rodriguez
executiveJustin, we're picking you up without any issues.
Justin Lake
analystI figured we could squeeze in another question about expenses as we move through 2023. For example, Andrew mentioned Micra earlier — you'll be rolling that out across the year. So I'm just trying to see whether there's any light at the end of the tunnel as the year progresses. Freyser costs for the year. You won't actually see that benefit, but by the end of '23 you'd be sitting at a higher run rate on savings than you had during the year. I was also considering what you said about contract labor coming in above your expectations and that it should hopefully ease during 2023. So I'm curious whether you could share some figures on that — for example, within that cost reduction effort, what portion is Macera in that cross-cutting figure — and how much do you figure you could extract? What would the total savings be that you could run rate at 23%? Then perhaps you could tell us where your contract labor costs stand in Q3 and Q4, and how you expect them to trend through 23, so we could estimate an exit rate in three/
Javier Rodriguez
executiveYes. So to start, I believe your directional thinking is right, that the first half of the year will be more difficult than the second half. And for — I break it into 3 buckets. One, Q1 is invariably seasonally hard owing to revenue per treatment. That's simply how we handle the nonpayment or bad debt tied to deductibles and co-pays. Second is a mix of the savings from Mircera plus some other initiatives accumulating as the year goes on, paired with some pressures from contract labor and training easing as the year goes on. And lastly, IKC is a business we've generally assumed will deliver a stronger Q4 than other quarters, given the way revenue recognition operates. We saw — we're observing less of that pattern in 2022. We've seen more of the revenue we anticipated recognizing in Q4 show up earlier in the year. But once again, I think we expect a stronger Q4 for ITC, even though that isn't something you could annualize. So those are the items when it comes to quantifying some of this. Contract labor for Q3 is running at roughly 30 — somewhat above $30 million for the quarter; we expect that to tick down a bit in Q4 and Q1 and then truly begin falling starting Q2 of next year, though we're assuming it stays elevated compared with our historical rate, which was nearly negligible. That covers contract labor; as for measuring the size of the cost savings, we've identified $150 million for next year at the midpoint of the range. Mircera makes up the largest piece of that. Second comes the footprint realignment, and third is the G&A. We won't provide particular figures on those items, though I believe that should help you land in the right ballpark for those three numbers.
Joel Ackerman
executiveUnderstood. Perhaps with Setra, the fourth-quarter run rate would essentially be twice the benefit, meaning it covers the annualized figure, but will it be something that's roughly ratable across the year, so the exit in the second and fourth quarters is going to be considerably higher? — compared with the full year overall. That's difficult to say, Justin; this — bear in mind, this is a effort that's intensive operationally. In the end, it's physicians who do the prescribing, not us, and it will come down to how they're thinking about it, how long it takes them to integrate the information, how many will make the change and when. So I don't believe we're ready to make a prediction on that.
Justin Lake
analystAll right, and my final question concerns revenue per treatment. You mentioned there were several moving pieces that helped revenue per treatment. First, could you quantify that in dollars of revenue per treatment — how much of a benefit did you see? I'm just trying to get a handle on, one, the size of that benefit this quarter, and two, whether it's a sensible run rate to consider heading into Q4? And then finally, perhaps you could provide a figure for that decline in commercial mix among commercial treatments. Yes. So I believe you can view the quarter as having gotten a lift of $2 to $3 from ordinary variability; we observe that constantly. If you're after a solid exit run rate, I'd say $365 RPT is a sensible exit run rate for Q4 and for the full year of 2022 from which to construct your '23 figure. Regarding commercial mix, it declined by a few basis points this quarter. So genuinely not material. I believe it was 10.4% in the prior quarter and it rounds to 10.3% in this one, but the change was quite minor.
Javier Rodriguez
executiveThank you, Aman. As all of you can tell from the entire discussion, providing guidance is more difficult given the COVID uncertainty around volume and the labor dynamics we've discussed. We, naturally, are striving extremely hard to deliver our best estimate and now are assuming they will remain elevated for some period. Let me wrap up with a few remarks. First, these are extremely difficult times for DaVita, and they are difficult times for the wider kidney care community and every health care provider; yet as I step back from this particular moment and gaze further ahead, I cannot help but state that we are exceptionally well positioned to differentiate and outperform because of our team's experience, the clarity of our strategy and the strength of our balance sheet. I'm grateful for your time today. Have a good day. Take care.
Operator
operatorThanks. That brings today’s call to a close. We appreciate everyone for joining in. You’re free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.